CORT

Corcept TherapeuticsNasdaqCM:CORT Stock Report

Market Cap

US$2.3b

7D

-0.8%

1Y

18.8%

Updated

22 Sep, 2021

Data

Company Financials +
CORT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

CORT Overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.

Corcept Therapeutics Competitors

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.4b

Price History & Performance

Summary of all time highs, changes and price drops for Corcept Therapeutics
Historical stock prices
Current Share PriceUS$20.27
52 Week HighUS$16.42
52 Week LowUS$31.18
Beta0.68
1 Month Change-3.01%
3 Month Change-10.59%
1 Year Change18.82%
3 Year Change49.26%
5 Year Change211.85%
Change since IPO65.74%

Recent News & Updates

Shareholder Returns

CORTUS PharmaceuticalsUS Market
7D-0.8%-1.5%-1.7%
1Y18.8%13.8%36.2%

Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 13.5% over the past year.

Return vs Market: CORT underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is CORT's price volatile compared to industry and market?
CORT volatility
CORT Beta0.68
Industry Beta0.64
Market Beta1

Stable Share Price: CORT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: CORT's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998236Joseph Belanoffhttps://www.corcept.com

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors.

Corcept Therapeutics Fundamentals Summary

How do Corcept Therapeutics's earnings and revenue compare to its market cap?
CORT fundamental statistics
Market CapUS$2.35b
Earnings (TTM)US$97.61m
Revenue (TTM)US$343.09m

24.1x

P/E Ratio

6.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CORT income statement (TTM)
RevenueUS$343.09m
Cost of RevenueUS$5.12m
Gross ProfitUS$337.97m
ExpensesUS$240.36m
EarningsUS$97.61m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.84
Gross Margin98.51%
Net Profit Margin28.45%
Debt/Equity Ratio0%

How did CORT perform over the long term?

See historical performance and comparison

Valuation

Is Corcept Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CORT ($20.27) is trading below our estimate of fair value ($53.95)

Significantly Below Fair Value: CORT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CORT is poor value based on its PE Ratio (24.1x) compared to the US Pharmaceuticals industry average (22x).

PE vs Market: CORT is poor value based on its PE Ratio (24.1x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: CORT is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: CORT is overvalued based on its PB Ratio (4.5x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Corcept Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

28.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CORT's forecast earnings growth (28.4% per year) is above the savings rate (2%).

Earnings vs Market: CORT's earnings (28.4% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CORT's revenue (16.2% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CORT's revenue (16.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CORT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Corcept Therapeutics performed over the past 5 years?

23.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CORT has high quality earnings.

Growing Profit Margin: CORT's current net profit margins (28.4%) are lower than last year (32.5%).


Past Earnings Growth Analysis

Earnings Trend: CORT's earnings have grown significantly by 23.4% per year over the past 5 years.

Accelerating Growth: CORT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CORT had negative earnings growth (-14.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.5%).


Return on Equity

High ROE: CORT's Return on Equity (18.7%) is considered low.


Financial Health

How is Corcept Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CORT's short term assets ($411.3M) exceed its short term liabilities ($45.4M).

Long Term Liabilities: CORT's short term assets ($411.3M) exceed its long term liabilities ($403.0K).


Debt to Equity History and Analysis

Debt Level: CORT is debt free.

Reducing Debt: CORT has no debt compared to 5 years ago when its debt to equity ratio was 86.6%.

Debt Coverage: CORT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CORT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CORT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CORT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CORT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CORT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CORT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Joseph Belanoff (64 yo)

22.67yrs

Tenure

US$5,762,102

Compensation

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...


CEO Compensation Analysis

Compensation vs Market: Joseph's total compensation ($USD5.76M) is above average for companies of similar size in the US market ($USD3.70M).

Compensation vs Earnings: Joseph's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CORT's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: CORT's board of directors are seasoned and experienced ( 19.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CORT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Corcept Therapeutics Incorporated's employee growth, exchange listings and data sources


Key Information

  • Name: Corcept Therapeutics Incorporated
  • Ticker: CORT
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.350b
  • Shares outstanding: 115.93m
  • Website: https://www.corcept.com

Number of Employees


Location

  • Corcept Therapeutics Incorporated
  • 149 Commonwealth Drive
  • Menlo Park
  • California
  • 94025
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 22:37
End of Day Share Price2021/09/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.